← Eichor
Condition: Advanced Soft Tissue Sarcoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Advanced Soft Tissue Sarcoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study Evaluating the Efficacy and Safety of Risvutatug Rezetecan in Participants With Advanced Sarcomas (EMBOLD Sarcom
Phase 1/Phase 2 · 6 location(s) · GlaxoSmithKline · NCT07602777Superiority Trial Evaluating Digitalized Information Media for Patients With Advanced Sarcomas Receiving Systemic Treatm
NA · 11 location(s) · Centre Oscar Lambret · NCT06211257Anti-GD2 ADC M3554 in Advanced Solid Tumors
Phase 1 · 11 location(s) · EMD Serono Research & Development Institute, Inc. · NCT06641908Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination with Radiotherapy in Soft Tissue Sarcom
Phase 1/Phase 2 · 4 location(s) · Grupo Espanol de Investigacion en Sarcomas · NCT05146440Sequential Infusion of CD146-Targeted and HER2-Targeted CAR T Cells in Patients With Advanced Sarcomas
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07066982Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Tango Therapeutics, Inc. · NCT05732831Vebreltinib for Advanced or Metastatic CCS
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07153887Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With
Phase 1/Phase 2 · 10 location(s) · Anocca AB · NCT07145450Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma
Phase 2 · 1 location(s) · CNBG-Virogin Biotech (Shanghai) Ltd. · NCT06126510A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Phase 1/Phase 2 · 1 location(s) · Blueprint Medicines Corporation · NCT07629960At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470Geno-radiomics Based Model for Evaluation of Immunotherapy and Targeted Therapy for Advanced Soft Tissue Sarcoma
Phase N/A · 1 location(s) · Peking Union Medical College Hospital · NCT06062927NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma
Phase 1 · 2 location(s) · Centre Hospitalier Universitaire Vaudois · NCT06889766Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma
Phase 1 · 1 location(s) · Sun Yat-sen University · NCT07648069X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma
Phase 1 · 4 location(s) · Immunolight, LLC · NCT04389281Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
Phase 2 · 1 location(s) · Gabriel Tinoco · NCT06528769KXV01 Injection in Patients With Advanced Solid Tumor (Including Osteosarcoma and Sarcoma)
Phase 1 · 1 location(s) · TCRx Therapeutics Co.Ltd · NCT07596693A Study of RNK08954 in Subjects With Advanced Solid Tumors With KRAS ((Kirsten Rat Sarcoma) G12D Mutation
Phase 1/Phase 2 · 6 location(s) · Ranok Therapeutics (Hangzhou) Co., Ltd. · NCT06667544BostonGene and Exigent Genomic INsight Study
Phase N/A · 7 location(s) · BostonGene · NCT06272864PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA)
Phase 2 · 1 location(s) · Ruijin Hospital · NCT06074692A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma
Phase 2 · 1 location(s) · Beijing Konruns Pharmaceutical Co., Ltd. · NCT06564272A Phase 2 Pilot Study to Evaluate the Safety and the Anti-Tumour Activity of the Myc Inhibitor OMO-103 Administered Intr
Phase 2 · 1 location(s) · Vall d'Hebron Institute of Oncology · NCT06650514Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma
Phase 2 · 7 location(s) · Italian Sarcoma Group · NCT04305548A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembroliz
Phase 1/Phase 2 · 9 location(s) · ImmVira Pharma Co. Ltd · NCT04370587A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agent
Phase 1/Phase 2 · 8 location(s) · Bristol-Myers Squibb · NCT07223047A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
Phase 1 · 6 location(s) · SEED Therapeutics, Inc. · NCT07197554A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangement
Phase 1/Phase 2 · 165 location(s) · Turning Point Therapeutics, Inc. · NCT03093116Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Second Affiliated Hospital of Guangzhou Medical University · NCT05187338A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiat
Phase 1 · 2 location(s) · Memorial Sloan Kettering Cancer Center · NCT05607095
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.